Physician profile
Michael Simmons
NPI 1447349915
$820.27
in general payments reported to CMS, 2019-2025
15 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Primary Podiatric Medicine provider received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $37.30 · 2021: $58.48 · 2023: $48.43 · 2024: $44.05 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $234.63 | 2019-2024 | Collagenase Santyl, Regranex |
| Organogenesis INC. | $141.65 | 2019-2025 | Apligraf |
| Treace Medical Concepts, INC. | $75.42 | 2025 | |
| Merck Sharp & Dohme LLC | $68.88 | 2019 | |
| Zimmer Biomet Holdings, INC. | $43.83 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $41.32 | 2021-2025 | Nuzyra |
| Kci USA, INC. | $34.48 | 2020-2021 | |
| Averitas Pharma INC. | $30.68 | 2025 | Qutenza |
| Kerecis Limited | $29.20 | 2019 | |
| Acell, INC. | $25.41 | 2019 | |
| Stryker Corporation | $20.77 | 2019 | |
| Podimetrics, INC. | $20.10 | 2025 | Smartmat |
| Solventum Corporation | $19.83 | 2025 | Kerramax Care, Activ.A.C., Promogran Prisma |
| Melinta Therapeutics, LLC | $18.61 | 2019 | |
| Stimwave Technologies Incorporated | $15.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.